Back to Search
Start Over
Prospective Application of Two New Pyridine-Based Zinc (II) Amide Carboxylate in Management of Alzheimer's Disease: Synthesis, Characterization, Computational and in vitro Approaches.
- Source :
-
Drug design, development and therapy [Drug Des Devel Ther] 2021 Jun 21; Vol. 15, pp. 2679-2694. Date of Electronic Publication: 2021 Jun 21 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Background: Alzheimer's disease (AD) is a neurodegenerative illness described predominantly by dementia. Even though Alzheimer's disease has been known for over a century, its origin remains a mystery, and researchers are exploring many therapy options, including the cholinesterase technique. A decreased acetylcholine ACh neurotransmitter level is believed to be among the important factors in the progression of Alzheimer's disease.<br />Methods: In continuation of synthesizing potential anti-Alzheimer agents and known appreciative pharmacological potential of amide-containing compounds, this study presents the synthesis of two novel amide-based transition metal zinc (II) complexes, AAZ7 and AAZ8, attached with a heterocyclic pyridine ring, which was synthesized and characterized by Fourier transform infrared spectroscopy (FT-IR), elemental analysis, <superscript>1</superscript> H&#95;NMR, and <superscript>13</superscript> C&#95;NMR. FT-IR spectroscopic records showed the development of bidentate ligand as Δν value was decreased in both complexes when compared with the free ligand. Both of the synthesized complexes were analyzed for acetylcholinesterase and butyrylcholinesterase inhibitory potential along with the antioxidizing activity.<br />Results: Importantly, the complex of AAZ8 exhibited more potent activity giving IC <subscript>50</subscript> values of 14 µg/mL and 18µg/mL as AChE and BChE cholinesterase inhibitors, respectively, when compared with standard positive control galantamine. Interestingly, AAZ8 also displayed promising antioxidant potential by showing IC <subscript>50</subscript> values of 35 µg/mL for DPPH and 29 µg/mL for ABTS in comparison with positive control ascorbic acid.<br />Conclusion: Herein, we report two new amide carboxylate zinc (II) complexes which were potentially analyzed for various biological applications like acetylcholinesterase (AChE), butyrylcholinesterase (BChE) inhibitory potentials, and antioxidant assays. Computational docking studies also simulated results to understand the interactions. Additionally, thermodynamic parameters utilizing molecular dynamic simulation were performed to determine the ligand protein stability and flexibility that supported the results. Studies have shown that these compounds have the potential to be good anti-Alzheimer candidates for future studies due to inhibition of cholinesterase enzymes and display of free radical scavenging potential against DPPH as well as ABTS free radicals.<br />Competing Interests: The authors reported no conflicts of interest for this work.<br /> (© 2021 Zafar et al.)
- Subjects :
- Acetylcholinesterase drug effects
Alzheimer Disease physiopathology
Amides chemical synthesis
Amides chemistry
Amides pharmacology
Animals
Antioxidants chemical synthesis
Antioxidants chemistry
Butyrylcholinesterase drug effects
Carboxylic Acids chemical synthesis
Carboxylic Acids chemistry
Carboxylic Acids pharmacology
Cholinesterase Inhibitors chemical synthesis
Cholinesterase Inhibitors chemistry
Electrophorus
Free Radical Scavengers chemical synthesis
Free Radical Scavengers chemistry
Free Radical Scavengers pharmacology
Horses
Inhibitory Concentration 50
Molecular Docking Simulation
Pyridines chemical synthesis
Pyridines chemistry
Pyridines pharmacology
Zinc chemistry
Alzheimer Disease drug therapy
Antioxidants pharmacology
Cholinesterase Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1177-8881
- Volume :
- 15
- Database :
- MEDLINE
- Journal :
- Drug design, development and therapy
- Publication Type :
- Academic Journal
- Accession number :
- 34188447
- Full Text :
- https://doi.org/10.2147/DDDT.S311619